Metformin combined with enzalutamide for the treatment of castration-resistant prostate cancer

SAKK 08/14 IMPROVE

Coordinating investigator

PD Dr. med.
Christian
Rothermundt
Kantonsspital St. Gallen
+41 71 494 11 63 (direkt)

In this phase II trial, we investigate the efficacy of a combination of the drug metformin and a treatment with enzalutamide. We compare this combination with a treatment with enzalutamide only. This trial involves patients with castration-resistant prostate cancer (prostate cancer that does not react to a hormone therapy anymore).

Enzalutamide treatment is a type of hormone therapy and prevents the hormone testosterone from reaching the prostate cancer cells. Without testosterone, the cancer cells cannot grow, wherever they are in the body. Metformin is normally used in the treatment of diabetes and is an active substance that constrains the production of glucose in the liver and helps muscles to absorb glucose. However, metformin has demonstrated favorable effects on cancer treatment. There are clues that it may induce disease stabilization and improve metabolic endpoints in patients with castration-resistant prostate cancer. Therefore, adding metformin to enzalutamide might have a positive impact.

168 patients with metastasized, non small-cell prostate cancer may participate in this trial.

All trials